https://www.biopharmawatch.com/news/SMMT/ivonescimab-monotherapy-significant-benefit-pembrolizumab BiopharmaWatch en 2026-09-13T11:00:00.000Z Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-public-offering BiopharmaWatch en 2026-09-11T23:45:00.000Z BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants https://www.biopharmawatch.com/news/MRBK/meridian-corporation-fiduciary-duties-investigation BiopharmaWatch en 2026-09-11T22:48:00.000Z SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Meridian Corporation (NASDAQ: MRBK). https://www.biopharmawatch.com/news/SRRK/fda-approval-isembyld-apitegromab-sma BiopharmaWatch en 2026-09-11T22:25:00.000Z Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) https://www.biopharmawatch.com/news/ENBI.X/entheon-adopts-semi-annual-reporting BiopharmaWatch en 2026-09-11T22:18:00.000Z Entheon Adopts Semi-Annual Reporting https://www.biopharmawatch.com/news/CLLS/cellectis-conference-call-business-update-september-2026 BiopharmaWatch en 2026-09-11T20:30:00.000Z Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update https://www.biopharmawatch.com/news/CMPS/strata-mental-health-solutions-training-grant-comp360 BiopharmaWatch en 2026-09-11T20:10:00.000Z Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360 https://www.biopharmawatch.com/news/AGMB/agomab-appointments-marino-garcia-naimish-patel BiopharmaWatch en 2026-09-11T20:05:10.000Z Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors https://www.biopharmawatch.com/news/IBO/impact-biomedical-reverse-stock-split-merger-zoar-ltd BiopharmaWatch en 2026-09-11T20:05:00.000Z Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.) https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-canyon-1-trial-data BiopharmaWatch en 2026-09-11T20:01:00.000Z Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity https://www.biopharmawatch.com/news/PHAR/fda-approves-pharming-joenja-treatment-apds-children BiopharmaWatch en 2026-09-11T18:00:00.000Z FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.